40 research outputs found
Microbial contamination of laboratory constructed removable orthodontic appliances
OBJECTIVES: This study aims to determine whether laboratory constructed removable orthodontic appliances are free from microbial contamination prior to clinical use and to evaluate the dental hospital cross-infection procedures to ensure that patient-derived contamination does not enter the construction process, thereby propagating a cycle of cross-contamination.MATERIALS AND METHODS: The construction process of removable orthodontic appliances from three individuals was evaluated at every stage, from impression to final delivery of the appliance using molecular microbiological techniques. The bacterial profiles at each stage of appliance construction were obtained using denaturing gradient gel electrophoresis, along with the bacterial profiles of the three participants' saliva. This enabled the bacterial profiles found at each stage of construction to be compared directly with the saliva of the person for whom the appliance was being constructed. Bacteria were identified at each stage using 16S rDNA PCR amplification and sequence phylogeny.RESULTS: There was no evidence of bacterial cross-contamination from patients to the laboratory. The current process of disinfection of impression appears to be adequate. Contamination was found on the final removable appliances (0.97 × 10(2)-1.52 × 10(3) cfu ml(-1)), and this contamination occurred from within the laboratory itself.CONCLUSIONS: Every effort is made to reduce potential cross-infection to patients and dental professionals. Newly constructed removable appliances were shown not to be free from contamination with bacteria prior to clinical use, but this contamination is environmental. Further studies would be required to determine the level of risk this poses to patients.CLINICAL SIGNIFICANCE: Dental professionals have a duty of care to minimise or eradicate potential risks of cross-infection to patients and other members of the team. To date, much less attention has been paid to contamination from the orthodontic laboratory, so contamination and infection risks are unknown.</p
Blood conservation strategies at United States hospitals during the COVID-19 pandemic: Findings from a multi-institutional analysis - International Society of Blood Transfusion survey.
BackgroundDue to the coronavirus disease 2019 (COVID-19) pandemic, the transfusion medicine community has experienced unprecedented blood supply shortages since March 2020. As such, numerous changes to everyday practice have occurred with a specific emphasis on blood conservation. We sought to determine the strategies used to mitigate blood shortages and promote blood conservation during the pandemic.MethodsAn anonymous, 37-question survey was developed using Research Electronic Data Capture and distributed via e-mail to transfusion medicine specialists across the US obtained via publicly available databases.ResultsAmongst surveyed [41.1% response rate (51/124 institutions)], 98.0% experienced a product shortage, with the greatest number reporting red blood cell (RBC) shortages (92.0%). This led to 35.3% of institutions altering the composition and/or number of blood product suppliers, including a 100% increase in the number of institutions acquiring blood from organizations that connect hospital transfusion services with blood collection centers (e.g., Blood Buy) compared to before March 2020. Prospective triaging of blood products was the most common blood conservation strategy (68.1%), though 35.4% altered their RBC exchange or transfusion program for patients receiving chronic RBC transfusion/exchange. As a result of these changes, 78.6% of institutions reported that these changes resulted in a reduction in blood product usage, and 38.1% reported a decrease in product wastage.ConclusionsMost hospitals experienced the effects of the supply shortage, and many of them implemented blood conserving measures. Conservation strategies were associated with decreased blood utilization and waste, and future studies could evaluate whether these changes persist
Recommended from our members
The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors
Background: Females have higher RBC alloantibody prevalence than males, presumably due to exposure to non-self RBC antigens through pregnancy as well as transfusion. Given the lack of routinely available and longitudinal data on lifelong pregnancy and transfusion histories, few studies have been able to distinguish pregnancy versus transfusion as contributing risk factors for RBC alloantibody induction or for the persistence of RBC alloantibody detectability. We hypothesized that pregnancy would be an important source of persistently detected RBC alloantibodies and investigated this in a longitudinal blood donor database.
Study Design and Methods: Donor/donation data were obtained from 4 US blood centers from 2012-2016. RBC antibody screen results and antibody identification (using tube, gel, or solid phase), donor demographics, pregnancy history, and transfusion history were evaluated. Blood donors were included in this analysis if they had an RBC alloantibody detected at any given donation as long as they had at least one subsequent blood donation and antibody screen. Anti-D antibodies detected, but present for < 6 months in females <50 years old were presumed due to passive RhIg and were excluded from this analysis. RBC alloantibody persistence was defined as an RBC alloantibody detected at each subsequent donation following its initial identification and RBC alloantibody evanescence was defined as one or more subsequent donations without re-detection of the alloantibody. Rates of donor alloantibody persistence were calculated as blood donors with persistent alloantibodies divided by blood donors with any alloantibody, and patterns of persistence were characterized by donor sex and presumed alloantibody source exposure.
Results: 503 blood donors had a detectable RBC alloantibody and a follow-up antibody screen; 374 (74%) were female and 130 (26%) were male. Of the 374 alloimmunized females, 210 (56%) reported prior pregnancy and no transfusion, 124 (33%) reported prior pregnancy and transfusion, 26 (7%) reported no pregnancy or transfusion, and 12 (3%) reported prior transfusion and no pregnancy. 215/334 (64%) of previously pregnant females had RBC alloantibodies that remained detectable throughout the duration of the study. The mean duration of detectability for persistent antibodies in previously pregnant females was 640 days, compared to a mean time to disappearance of 183 days for evanescent antibodies. In contrast, males and all never-pregnant females were less likely to have persistently detectable antibodies, with 52% (87/167) being in this category (chi square p = 0.008). The mean duration of detectability for persistent antibodies in males and never-pregnant females was 576 days, compared to a mean time to disappearance of 290 days for evanescent antibodies. Previously pregnant females with a reported history of prior transfusion (n=124) had the highest rate (77%) of RBC alloantibody persistence. The alloantibody specificities of previously pregnant females included E (96), D (81), K (78), Fy (21), C (47), MNS (38), and Jk (18). Of these, Fy and non-passive D were most likely to be persistent (each 86%), followed by C (79%), K (74%), E (59%), Jk (55%), and MNS (34%).
Conclusion: Data from this multi-center blood donor database, with documented life-long pregnancy and transfusion histories, highlight the role that pregnancy plays in RBC alloimmunization. Importantly, pregnancy was an exposure source in almost all studied RBC alloimmunized female healthy blood donors and was the sole reported exposure in the majority of donors. Although these data cannot definitively identify the source of non-self blood group antigen exposure in blood donors with both pregnancy and transfusion histories, they show that antibodies in previously pregnant females are long lasting. It is possible that length of exposure to non-self RBC antigens, the relatively young age of females during childbearing, long standing fetal white blood cell microchimerism in the maternal circulation, or other variables may impact plasma cell longevity and/or antibody production, and thus the persistence of pregnancy (versus transfusion) associated RBC alloantibodies. Given the numbers and persistence of such RBC alloantibodies, we recommend that pregnancy history be taken into consideration in all RBC alloimmunization studies involving females at or beyond childbearing age.
Disclosures
Spencer: HemaStrat, LLC: Membership on an entity's Board of Directors or advisory committees